Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.

Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022 03; 7(3):254-261.

View in: PubMed

subject areas

Clinical Trials as Topic
Eye Diseases
Humans
Inflammatory Bowel Diseases
Rheumatic Diseases
Skin Diseases

authors with profiles

David T. Rubin